Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HAE Haemonetics	$62.53 +1.0%	$62.83	$55.30 ▼ $97.97	$3.14B	0.41	691,035 shs	446,456 shs
ICUI ICU Medical	$135.66 -1.1%	$143.81	$95.44 ▼ $196.26	$3.34B	0.86	274,007 shs	164,550 shs
MMSI Merit Medical Systems	$94.61 -0.1%	$98.60	$73.67 ▼ $111.45	$5.59B	0.85	497,926 shs	1.28 million shs
VIVO Meridian Bioscience	$33.97	$33.70	$20.35 ▼ $34.38	$1.50B	0.23	973,737 shs	N/A

20 Stocks to Sell Now

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HAE Haemonetics	+1.03%	+9.50%	-2.83%	-11.44%	-27.48%
ICUI ICU Medical	-1.09%	-2.17%	-8.78%	-21.27%	+40.26%
MMSI Merit Medical Systems	-0.06%	+4.09%	-8.77%	-9.59%	+27.80%
VIVO Meridian Bioscience	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HAE Haemonetics	4.6162 of 5 stars	4.4	2.0	4.3	3.7	1.7	1.3
ICUI ICU Medical	3.8329 of 5 stars	2.5	3.0	3.9	1.9	1.7	1.9
MMSI Merit Medical Systems	4.0575 of 5 stars	3.5	1.0	3.8	2.7	2.5	1.3
VIVO Meridian Bioscience	0.379 of 5 stars	0.0	0.0	4.2	0.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HAE Haemonetics	2.78	Moderate Buy	$101.22	61.88% Upside
ICUI ICU Medical	3.00	Buy	$162.67	19.91% Upside
MMSI Merit Medical Systems	3.00	Buy	$109.00	15.21% Upside
VIVO Meridian Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VIVO, MMSI, ICUI, and HAE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2025	MMSI Merit Medical Systems	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $108.00
4/25/2025	MMSI Merit Medical Systems	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$116.00 ➝ $108.00
4/25/2025	MMSI Merit Medical Systems	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$116.00 ➝ $100.00
4/25/2025	MMSI Merit Medical Systems	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$111.00 ➝ $103.00
4/25/2025	MMSI Merit Medical Systems	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$111.00 ➝ $110.00
4/23/2025	MMSI Merit Medical Systems	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$116.00 ➝ $112.00
4/21/2025	ICUI ICU Medical	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$209.00 ➝ $191.00
4/11/2025	MMSI Merit Medical Systems	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$111.00 ➝ $111.00
4/9/2025	MMSI Merit Medical Systems	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$116.00 ➝ $116.00
4/8/2025	ICUI ICU Medical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/28/2025	MMSI Merit Medical Systems	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$120.00

(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HAE Haemonetics	$1.37B	2.29	$5.97 per share	10.48	$18.05 per share	3.46
ICUI ICU Medical	$2.38B	1.40	$12.73 per share	10.66	$87.96 per share	1.54
MMSI Merit Medical Systems	$1.36B	4.12	$4.32 per share	21.89	$20.81 per share	4.55
VIVO Meridian Bioscience	$333.02M	4.49	$1.78 per share	19.13	$8.41 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HAE Haemonetics	$117.56M	$2.54	24.62	12.41	1.11	9.47%	23.66%	8.82%	5/8/2025 (Estimated)
ICUI ICU Medical	-$29.66M	-$4.83	N/A	24.94	N/A	-4.74%	5.05%	2.42%	5/8/2025 (Estimated)
MMSI Merit Medical Systems	$94.41M	$2.03	46.38	25.23	2.34	9.05%	15.61%	8.38%	N/A
VIVO Meridian Bioscience	$42.46M	$0.97	35.02	∞	N/A	12.70%	16.74%	13.09%	N/A

Latest VIVO, MMSI, ICUI, and HAE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2025	HAE Haemonetics	$1.22	N/A	N/A	N/A	$329.38 million	N/A
5/8/2025	Q1 2025	ICUI ICU Medical	$1.23	N/A	N/A	N/A	$574.15 million	N/A
2/6/2025	Q3 2025	HAE Haemonetics	$1.20	$1.19	-$0.01	$0.74	$354.46 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
ICUI ICU Medical	N/A	N/A	N/A	N/A	N/A
MMSI Merit Medical Systems	N/A	N/A	N/A	N/A	N/A
VIVO Meridian Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HAE Haemonetics	1.35	3.97	2.55
ICUI ICU Medical	0.75	2.29	1.03
MMSI Merit Medical Systems	0.57	5.36	3.82
VIVO Meridian Bioscience	0.07	3.63	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HAE Haemonetics	99.67%
ICUI ICU Medical	96.10%
MMSI Merit Medical Systems	99.66%
VIVO Meridian Bioscience	89.72%

Insider Ownership

Company	Insider Ownership
HAE Haemonetics	1.80%
ICUI ICU Medical	1.50%
MMSI Merit Medical Systems	3.70%
VIVO Meridian Bioscience	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HAE Haemonetics	2,820	50.24 million	49.33 million	Optionable
ICUI ICU Medical	14,500	24.61 million	22.84 million	Optionable
MMSI Merit Medical Systems	6,850	59.07 million	56.12 million	Optionable
VIVO Meridian Bioscience	702	44.01 million	43.00 million	Optionable

VIVO, MMSI, ICUI, and HAE Headlines

Recent News About These Companies

Meridian Bioscience Introduces New Enzyme Stabilization Services for Molecular Diagnostics

April 24 at 6:19 AM | finance.yahoo.com

Meridian Bioscience Inc (VIVO)

April 10, 2025 | uk.investing.com

India's smartphone mkt grows 6%, Vivo tops

November 13, 2024 | rediff.com

Meridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to Sustainability

November 7, 2024 | finance.yahoo.com

Meridian Bioscience Gets $500K Top Prize in POC Blood Lead Test Challenge

October 28, 2024 | 360dx.com

Precision BioSciences Launches First Hepatitis B Gene-Editing Trial

October 26, 2024 | precisionmedicineonline.com

Will iQOO 13 launch at same price as iQOO 12? New leak provides major hint

October 25, 2024 | msn.com

Editas strengthens in vivo gene therapy strategy via $238M LNP tech pact with Genevant

October 22, 2024 | fiercebiotech.com

Vivo and Arm collaborate on chip technology innovation, launch joint lab

October 21, 2024 | digitimes.com

vivo and Arm collaborate on chip technology innovation with the unveiling of the vivo Arm Joint Lab

October 18, 2024 | malaysiasun.com

Meridian Growth Legacy MERDX

October 17, 2024 | morningstar.com

Serán Bioscience snags investment from Bain Capital Life Sciences

September 17, 2024 | pehub.com

Vivo T3 Ultra launch on September 12 – check what’s in store for India market

September 6, 2024 | financialexpress.com

Vivo V40 vs Realme GT 6T: How the two mid-range smartphones compare

August 11, 2024 | msn.com

Fast-growing MBX Biosciences raises another $63.5 million in funding

August 6, 2024 | ibj.com

Meridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic Manufacturers

July 23, 2024 | finance.yahoo.com

Grant supports Lift Biosciences’ evaluation of IMAN cell therapies in humanized in vivo model systems

May 17, 2024 | bioworld.com

Biomerica, Inc. (BMRA)

May 11, 2024 | finance.yahoo.com

Vivo X100s Pro with new Dimensity 9300 Plus chip could be launching soon

March 24, 2024 | gizmochina.com

Vivo V30 Pro review: Flagship-grade imaging system in a slender form factor

March 13, 2024 | business-standard.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVO, MMSI, ICUI, and HAE Company Descriptions

Haemonetics NYSE:HAE

$62.53 +0.61 (+0.99%)

Closing price 04/25/2025 03:59 PM Eastern

Extended Trading

$62.50 -0.04 (-0.06%)

As of 04/25/2025 04:05 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

ICU Medical NASDAQ:ICUI

$135.66 -1.50 (-1.09%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$135.88 +0.22 (+0.16%)

As of 04/25/2025 07:43 PM Eastern

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Merit Medical Systems NASDAQ:MMSI

$94.61 -0.06 (-0.06%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$93.10 -1.51 (-1.60%)

As of 04/25/2025 07:52 PM Eastern

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.

Meridian Bioscience NASDAQ:VIVO

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time